References:
1. Weekly Hospitalization Trends - Johns Hopkins Coronavirus Resource
Center. Johns Hopkins Coronavirus Resource Center.
2. Johns Hopkins Coronavirus Resource Center. Johns Hopkins Coronavirus
Resource Center.
3. Ritchie H ME, Rodés-Guirao L et al. Coronavirus Pandemic (COVID-19).
Our World in Data.
4. Ahmad FB CJ, Miniño A, Anderson RN Provisional Mortality Data —
United States, 2020 MMWR Morb Mortal Wkly Rep
2021;70:519–522.70:519-22.
5. COVID Data Tracker. Centers for Disease Control and Prevention.
6. Monitoring of COVID-19 Infection In Lebanon - 12/4/2022.
7. aPetrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak
Y, et al. Factors associated with hospital admission and critical
illness among 5279 people with coronavirus disease 2019 in New York
City: prospective cohort study. Bmj. 2020;369:m1966; bUnderlying Medical
Conditions Associated with Higher Risk for Severe COVID-19: Information
for Healthcare Professionals. Centers for Disease Control and
Prevention; cLiang W, Liang H, Ou L, Chen B, Chen A, Li C, et al.
Development and Validation of a Clinical Risk Score to Predict the
Occurrence of Critical Illness in Hospitalized Patients With COVID-19.
JAMA Internal Medicine. 2020;180(8):1081-9; dCariou B, Pichelin M,
Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C, et al. Phenotypic
characteristics and prognosis of newly diagnosed diabetes in
hospitalized patients with COVID-19: Results from the CORONADO study.
Diabetes Res Clin Pract. 2021;175:108695.
8. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et
al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19)
Outbreaks in the United States. Clin Infect Dis. 2021;73(12):2257-64.
9. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et
al. Infectious Diseases Society of America Guidelines on the Treatment
and Management of Patients with COVID-19. Clin Infect Dis. 2020.
10. Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19.
JAMA. 2021;325(10):1015-.
11. Fact Sheet for Healthcare Providers Emergency Use Authorization
(EUA) of Sotrovimab. U.S. Food and Drug Administration (FDA).
12. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci
DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing
Antibody Sotrovimab. N Engl J Med. 2021;385(21):1941-50.
13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al.
The Omicron variant is highly resistant against antibody-mediated
neutralization: Implications for control of the COVID-19 pandemic. Cell.
2022;185(3):447-56.e11.
14. Zahreddine NK, Haddad SF, Kerbage A, Kanj SS. Challenges of
coronavirus disease 2019 (COVID-19) in Lebanon in the midst of the
economic collapse. Antimicrobial Stewardship & Healthcare Epidemiology.
2022;2(1):e67.
15. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019
(COVID-19) Treatment Guidelines. National Institutes of Health. 2022. .
16. Saheb Sharif-Askari F, Ali Hussain Alsayed H, Tleyjeh I, Saheb
Sharif-Askari N, Al Sayed Hussain A, Saddik B, et al. Sotrovimab lowers
the risk of COVID-19 related hospitalization or death in a large
population cohort in the United Arab Emirates. Clin Pharmacol Ther.
2022.
17. Efficacy and safety of two neutralising monoclonal antibody
therapies, sotrovimab and BRII-196 plus BRII-198, for adults
hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet
Infect Dis. 2022;22(5):622-35.
18. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al.
Factors Associated With Death in Critically Ill Patients With
Coronavirus Disease 2019 in the US. JAMA Internal Medicine.
2020;180(11):1436-47.
19. Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, et
al. Real World Evidence of the Neutralizing Monoclonal Antibody
Sotrovimab for Preventing Hospitalization and Mortality in COVID-19
Outpatients. medRxiv. 2022.
20. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation
of COVID-19 Mortality and Adverse Outcomes in US Patients With or
Without Cancer. JAMA Oncology. 2022;8(1):69-78.
21. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients
in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol.
2020;21(3):335-7.
22. Nader Marta G, Colombo Bonadio R, Nicole Encinas Sejas O, Watarai G,
Mathias Machado MC, Teixeira Frasson L, et al. Outcomes and Prognostic
Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19.
JCO Global Oncology. 2021(7):1084-92.